4.6 Article

The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 8, 期 1, 页码 137-145

出版社

WILEY
DOI: 10.1111/j.1538-7836.2009.03665.x

关键词

coagulation; O-glycosylation; von Willebrand factor

资金

  1. British Heart Foundation [FS/06/069/21490]
  2. Biotechnology and Biological Sciences Research Council [SF19107, B19088, BBF0083091]
  3. NIHR Biomedical Research Centre Funding Scheme

向作者/读者索取更多资源

Background: von Willebrand factor (VWF) is a key component for maintenance of normal hemostasis. Its glycan moieties, accounting for about 20% of its molecular weight, have been shown to affect many of its properties. Previous studies reported correlations between VWF secretion, half-life and the nature or presence of its N-glycans, and more importantly between VWF plasma level and the type of N-linked ABH antigens. Despite the presence of 10 predicted O-glycosylation sites, the O-glycome remains poorly characterized, impairing the complete elucidation of its influence on VWF functions. So far only a single glycan structure, a disialyl core 1 glycan, has been identified. Objectives: To define an exhaustive profile of the VWF O-glycan structures to help the understanding of their role in VWF regulation and properties. Methods: Plasma-derived VWF O-linked sugars were isolated and analyzed using state-of-the-art mass spectrometry methodologies. Results and conclusions: We provide here a detailed analysis of the human plasma-derived VWF O-glycome. Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF. Amongst the newly determined structures are unusual tetra-sialylated core 1 O-glycans and ABH antigen-containing core 2 O-glycans. In conjunction with current models explaining VWF activity, knowledge of the complete O-glycome will facilitate research aimed at providing a better understanding of the influence of glycosylation on VWF functions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock

Ingrid Bekono-Nessah, Alex Rosenburg, Christopher T. Bowles, Fernando Riesgo-Gil, Ulrich Stock, Richard R. Szydlo, Mike Laffan, Deepa J. Arachchillage

Summary: Major bleeding and thrombosis significantly increase the 1-year mortality in HVAD patients. Optimal perioperative hemostasis and anticoagulation remain crucial for HVAD patients.

PERFUSION-UK (2023)

Article Hematology

Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome - Single Centre Observational Study in the United Kingdom

Hithin Noble, Christina Crossette-Thambiah, Zain Odho, Nilanthi Karawitage, Karen Logan, Charis Pericleous, Mike Laffan, Deepa J. Arachchillage

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Article Pharmacology & Pharmacy

The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial

Alexander J. Robbins, Nur Amalina Che Bakri, Edward Toke-Bjolgerud, Aaron Edwards, Asha Vikraman, Cathy Michalsky, Michael Fossler, Nana-Marie Lemm, Savviz Medhipour, William Budd, Athanasia Gravani, Lisa Hurley, Vikas Kapil, Aimee Jackson, Dagan Lonsdale, Victoria Latham, Michael Laffan, Neil Chapman, Nichola Cooper, Richard Szydlo, Joseph Boyle, Katrina M. Pollock, David Owen

Summary: COVID-19 causes significant thrombosis and coagulopathy, with elevated D-dimer as an adverse outcome predictor. The mechanism of this coagulopathy is not clear, but it may involve the accumulation of pro-inflammatory angiotensin-II due to the loss of angiotensin-converting enzyme 2 activity. A study investigated the effect of TRV027, a synthetic angiotensin-1-7 analogue, on D-dimer levels in 30 hospitalized COVID-19 patients. The results showed a numerical decrease in D-dimer in the TRV027 group, but this difference did not reach statistical significance.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Hematology

Humanistic burden of problem joints for children and adults with haemophilia

Tom Burke, Idaira Rodriguez-Santana, Pratima Chowdary, Randall Curtis, Kate Khair, Michael Laffan, Paul Mclaughlin, Declan Noone, Brian O'Mahony, John Pasi, Mark Skinner, Jamie O'Hara

Summary: The problem joint (PJ) concept was developed to address patient-centric needs for a more holistic assessment of joint morbidity for people with haemophilia (PwH). This study used data analysis to quantify the humanistic burden of PJs in PwH and further validated the PJ outcome measure. The results showed that PJs are associated with decreased health-related quality of life and overall work productivity loss in PwH. Therefore, the importance of PJs should be considered in clinical and health policy assessments of joint health.

HAEMOPHILIA (2023)

Review Biochemistry & Molecular Biology

Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome

Deepa J. Arachchillage, Mike Laffan, Charis Pericleous

Summary: Antiphospholipid syndrome (APS) is a highly prothrombotic disorder caused by thrombo-inflammatory antiphospholipid antibodies (aPL) that lead to thrombosis through various mechanisms. Obstetric complications in APS are a result of placental thrombosis, inflammation, and complement activation. While anticoagulation is the main treatment, it may not effectively prevent thrombosis recurrence in some patients, especially those with triple positive aPL.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Hematology

Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: Multicentre observational study in the UK

Deepa Arachchillage, Indika Rajakaruna, Zain Odho, Mike Makris, Mike Laffan

Summary: The controversy of post-discharge thromboprophylaxis in COVID-19 patients remains. This observational study across 26 NHS Trusts aimed to determine the impact of thromboprophylaxis on hospital acquired thrombosis (HAT) in discharged patients. The study found no difference in HAT between patients discharged with and without thromboprophylaxis, but increasing age and smoking significantly increased the risk of HAT.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Hematology

An expert consensus to define how higher standards of equitable care for von Willebrand disease can be achieved in the UK and Republic of Ireland

Mike Laffan, Gary Benson, Cathy Farrelly, Keith Gomez, April Jones, Rhona Maclean, James O'Donnell, Michelle Lavin

Summary: Von Willebrand Disease (VWD) is a common inherited bleeding disorder, but awareness and understanding of the disease lags behind other bleeding disorders, causing delays in diagnosis and treatment. Updated national guidelines are needed to improve the management of VWD and provide equitable care for both men and women. Through a survey and analysis conducted by a panel of experts, eight recommendations were derived to enhance the detection and management of VWD.

HAEMOPHILIA (2023)

Letter Critical Care Medicine

Continuation of therapeutic dose heparin for critically ill patients with COVID-19

Charlotte A. Bradbury, Patrick R. Lawler, Bryan J. McVerry, Ryan Zarychanski, REMAP C A P Investigators

INTENSIVE CARE MEDICINE (2023)

Article Medicine, General & Internal

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

J. Mahlangu, R. Kaczmarek, A. von Drygalski, S. Shapiro, S. -C. Chou, M. C. Ozelo, G. Kenet, F. Peyvandi, M. Wang, B. Madan, N. S. Key, M. Laffan, A. L. Dunn, J. Mason, D. V. Quon, E. Symington, A. D. Leavitt, J. Oldenburg, H. Chambost, M. T. Reding, K. Jayaram, H. Yu, R. Mahajan, K. -M. Chavele, D. B. Reddy, J. Henshaw, T. M. Robinson, W. Y. Wong, S. W. Pipe

Summary: This study demonstrates the long-term effectiveness and safety of valoctocogene roxaparvovec therapy in reducing bleeding events in men with severe hemophilia A. The pharmacokinetic modeling suggests a half-life of 123 weeks for the transgene-derived factor VIII production system. Models also indicate a similar relationship between factor VIII activity and bleeding episodes as observed in individuals with mild-to-moderate hemophilia A using epidemiologic data.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Cell Biology

Multiple myeloma and its treatment contribute to increased platelet reactivity

Joanne L. Mitchell, Dalia Khan, Rekha H. Rana, Neline Kriek, Amanda J. Unsworth, Tanya Sage, Alexander P. Bye, Michael Laffan, Susan Shapiro, Anjan Thakurta, Henri Grech, Karthik Ramasamy, Jonathan M. Gibbins

Summary: This pilot study demonstrated that patients with MGUS, SM and MM have increased platelet reactivity and prothrombotic potential, which is further exacerbated by treatment with Lenalidomide.

PLATELETS (2023)

Article Hematology

Safety and Efficacy of Therapeutic Anticoagulation with Subcutaneous Unfractionated Heparin in Patients with Renal Failure

Giulia Simini, Frances Akor, Richard Szydlo, Michael Laffan, Deepa R. J. Arachchillage

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Article Hematology

Traumatic coagulopathy in the older patient: analysis of coagulation profiles from the Activation of Coagulation and Inflammation in Trauma-2 (ACIT-2) observational, multicenter study

Nicola S. Curry, Ross Davenport, Henna Wong, Christine Gaarder, Par Johansson, Nicole P. Juffermans, Marc Maegele, Jakob Stensballe, Karim Brohi, Mike Laffan, Simon J. Stanworth

Summary: This study reports coagulation profiles stratified by age and finds an association between age and hemostatic capability. Although similar patterns of coagulation abnormalities are observed across age groups following severe injury/shock, thresholds for single clotting factors differ. These age-related differences may need to be considered in clinical treatments (e.g., transfusion therapy).

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Thombosis, major bleeding, and survival in COVID-19 supported by veno-venous extracorporeal membrane oxygenation in the first vs second wave: a multicenter observational study in the United Kingdom

Deepa J. Arachchillage, Anna Weatherill, Indika Rajakaruna, Mihaela Gaspar, Zain Odho, Graziella Isgro, Lenka Cagova, Lucy Fleming, Stephane Ledot, Mike Laffan, Richard Szydlo, Rachel Jooste, Ian Scott, Alain Vuylsteke, Hakeem Yusuff

Summary: Thrombosis and major bleeding are common complications in V-V ECMO patients and significantly increase mortality. Age and elevated creatinine level are associated with increased mortality, while the type of thrombosis has different effects on mortality.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Meeting Abstract Hematology

Outcomes in COVID-19 supported by ECMO in the first vs second wave -multicentre observational study

Deepa J. Arachchillage, Indika Rajakaruna, Mike Laffan, Richard Szydlo, Zain Odho, Ian Scott, Stephane Ledot, Alain Vuylsteke, Hakeem Yusuff

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Meeting Abstract Hematology

Thrombocytosis and acquired bleeding disorders in patients with myeloproliferative neoplasms

Giulia Simini, Saravanan Vinayagam, Nilanthi Karawitage, Golzar Mobayen, Anupama Krishnamoorthi, Andrew James Innes, Michael Laffan, Deepa Jayakody Arachchillage

BRITISH JOURNAL OF HAEMATOLOGY (2023)

暂无数据